MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Net Debt 2011-2026 | ALNY
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -604 M | 100 M | 250 M | 193 M | -498 M | -268 M | -243 M | -390 M | -615 M | -43.6 M | -181 M | -75.2 M | -53.2 M | -51.4 M | -70.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 250 M | -615 M | -170 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M |  China |
 |
Aptorum Group Limited
APM
|
-2.77 M | $ 0.81 | 0.15 % | $ 4.42 M | China |
 |
argenx SE
ARGX
|
-89.9 M | $ 836.39 | -0.46 % | $ 25 B |  Niderland |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | USA |
 |
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-195 M | $ 234.52 | -0.2 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.44 | 3.42 % | $ 8.28 B |  Australia |
 |
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
-17.2 M | $ 1.24 | -0.8 % | $ 1.83 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
-935 M | $ 61.58 | -1.66 % | $ 11.7 B | USA |
 |
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | USA |
 |
Atea Pharmaceuticals
AVIR
|
-63.1 M | $ 4.56 | -1.94 % | $ 384 M | USA |
 |
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - |  Russia |
 |
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | USA |
 |
Capricor Therapeutics
CAPR
|
-12.5 M | $ 28.24 | 1.18 % | $ 756 M | USA |
 |
Axsome Therapeutics
AXSM
|
-205 M | $ 165.14 | -2.83 % | $ 8.22 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M |  Israel |
 |
CASI Pharmaceuticals
CASI
|
-36.5 M | $ 0.31 | -61.59 % | $ 42.2 M | USA |
 |
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | USA |
 |
Catalyst Biosciences
CBIO
|
-33.1 M | $ 12.21 | -3.48 % | $ 804 M | USA |
 |
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
3.36 B | $ 191.78 | -1.72 % | $ 28.1 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
1.86 M | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-3.05 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
-973 M | $ 110.5 | -0.35 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
2.28 B | $ 14.64 | -0.17 % | $ 4.52 B | USA |